| scholarly article | Q13442814 |
| P50 | author | Monte Willis | Q38322683 |
| Jonathan Schisler | Q43080201 | ||
| P2093 | author name string | Cam Patterson | |
| P2860 | cites work | Mutations in beta-myosin S2 that cause familial hypertrophic cardiomyopathy (FHC) abolish the interaction with the regulatory domain of myosin-binding protein-C | Q22008775 |
| Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain | Q24290911 | ||
| Mdm2 promotes the rapid degradation of p53 | Q24322597 | ||
| Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I | Q24558612 | ||
| Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy. Characterization Of cardiac transcript and protein | Q24561566 | ||
| Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3 | Q24673171 | ||
| Molecular determinants for the recruitment of the ubiquitin-ligase MuRF-1 onto M-line titin | Q27643507 | ||
| Regulation of p53 stability by Mdm2 | Q27860744 | ||
| A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance | Q28139924 | ||
| Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain | Q28142613 | ||
| Effect of acetylsalicylic acid on endogenous I kappa B kinase activity in lung epithelial cells | Q28174796 | ||
| Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy | Q28198707 | ||
| Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury | Q44210996 | ||
| Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway | Q44760490 | ||
| Approval summary for bortezomib for injection in the treatment of multiple myeloma | Q44951957 | ||
| Inhibition of the ubiquitin-proteasome pathway induces differential heat-shock protein response in cardiomyocytes and renders early cardiac protection | Q45713461 | ||
| A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). | Q46528602 | ||
| Bortezomib or high-dose dexamethasone for relapsed multiple myeloma | Q46549268 | ||
| Statins prevent NF-kappaB transactivation independently of the IKK-pathway in human endothelial cells | Q46624092 | ||
| Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury. | Q47282390 | ||
| COOH-terminal truncated cardiac myosin-binding protein C mutants resulting from familial hypertrophic cardiomyopathy mutations exhibit altered expression and/or incorporation in fetal rat cardiomyocytes | Q47898149 | ||
| CHIP chaperones wild type p53 tumor suppressor protein. | Q51578869 | ||
| CHIP, a cochaperone/ubiquitin ligase that regulates protein quality control, is required for maximal cardioprotection after myocardial infarction in mice. | Q51594198 | ||
| Chronic proteasome inhibition contributes to coronary atherosclerosis. | Q51739024 | ||
| Loss of Mdm4 results in p53-dependent dilated cardiomyopathy. | Q51751869 | ||
| Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: Effect on myocardial contractility | Q61896386 | ||
| Cardiac protein synthesis and degradation during thyroxine-induced left ventricular hypertrophy | Q70016121 | ||
| Unexpected cardiotoxicity in haematological bortezomib treated patients | Q80463636 | ||
| Functional properties of the titin/connectin-associated proteins, the muscle-specific RING finger proteins (MURFs), in striated muscle | Q82548298 | ||
| Protein synthesis and degradation during regression of thyroxine-induced cardiac hypertrophy | Q93524527 | ||
| Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants | Q28239896 | ||
| A molecular map of the interactions between titin and myosin-binding protein C. Implications for sarcomeric assembly in familial hypertrophic cardiomyopathy | Q28278861 | ||
| The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation | Q28280958 | ||
| Familial hypertrophic cardiomyopathy: from mutations to functional defects | Q28282839 | ||
| In vivo modeling of myosin binding protein C familial hypertrophic cardiomyopathy | Q28512273 | ||
| Regulation of microtubule dynamics and myogenic differentiation by MURF, a striated muscle RING-finger protein | Q28513866 | ||
| Atrophy, hypertrophy, and hypoxemia induce transcriptional regulators of the ubiquitin proteasome system in the rat heart | Q28574395 | ||
| Cardiac hypertrophy: the good, the bad, and the ugly | Q29615247 | ||
| Protein degradation and protection against misfolded or damaged proteins | Q29618400 | ||
| Structural evidence for the interaction of C-protein (MyBP-C) with actin and sequence identification of a possible actin-binding domain. | Q33338599 | ||
| A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma | Q33374572 | ||
| The ubiquitin signal: assembly, recognition and termination. Symposium on ubiquitin and signaling | Q34360569 | ||
| The kinase domain of titin controls muscle gene expression and protein turnover | Q34407820 | ||
| Certain pairs of ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) synthesize nondegradable forked ubiquitin chains containing all possible isopeptide linkages. | Q34617875 | ||
| MLN-519. Millennium/PAION | Q35123169 | ||
| Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, titin, and associated structures | Q35621909 | ||
| Loss of muscle-specific RING-finger 3 predisposes the heart to cardiac rupture after myocardial infarction | Q35721399 | ||
| Kinomics: methods for deciphering the kinome | Q36079218 | ||
| Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins | Q36088932 | ||
| Muscle ring finger protein-1 inhibits PKC{epsilon} activation and prevents cardiomyocyte hypertrophy | Q36322902 | ||
| Regulating the regulator: NF-kappaB signaling in heart | Q36583897 | ||
| Heart failure and protein quality control | Q36678579 | ||
| A ubiquitin mutant with specific defects in DNA repair and multiubiquitination | Q40015739 | ||
| Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex | Q40177208 | ||
| Differential regulation of cardiomyocyte survival and hypertrophy by MDM2, an E3 ubiquitin ligase | Q40341746 | ||
| Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide | Q40431933 | ||
| NF-kappa B and rel proteins in innate immunity | Q40519638 | ||
| A proteasome inhibitor confers cardioprotection | Q40580614 | ||
| Triggers for sudden cardiac death in the athlete. | Q41047262 | ||
| Biomolecular interactions between human recombinant β-MyHC and cMyBP-Cs implicated in familial hypertrophic cardiomyopathy | Q42046156 | ||
| Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling | Q42500888 | ||
| Muscle ring finger 1, but not muscle ring finger 2, regulates cardiac hypertrophy in vivo | Q42750583 | ||
| Ubiquitination and degradation of the anti-apoptotic protein ARC by MDM2. | Q42833116 | ||
| Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation | Q42917499 | ||
| PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated I kappa B alpha degradation | Q43800033 | ||
| Ubiquitin-proteasome pathway as a new target for the prevention of restenosis | Q43869296 | ||
| P433 | issue | 1 | |
| P921 | main subject | appetite | Q28578 |
| P304 | page(s) | 65-75 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Future Cardiology | Q15765184 |
| P1476 | title | Appetite for destruction: E3 ubiquitin-ligase protection in cardiac disease | |
| P478 | volume | 4 |
| Q28078724 | A Decade of Boon or Burden: What Has the CHIP Ever Done for Cellular Protein Quality Control Mechanism Implicated in Neurodegeneration and Aging? |
| Q37476330 | Allele-specific expression in the human heart and its application to postoperative atrial fibrillation and myocardial ischemia. |
| Q42770507 | Chaperoning myosin assembly in muscle formation and aging |
| Q33769449 | Effects of a Proteasome Inhibitor on Cardiomyocytes in a Pressure-Overload Hypertrophy Rat Model: An Animal Study |
| Q28296634 | Hold me tight: Role of the heat shock protein family of chaperones in cardiac disease |
| Q88664220 | Increasing Cardiomyocyte Atrogin-1 Reduces Aging-Associated Fibrosis and Regulates Remodeling in Vivo |
| Q36934990 | Metabolic derangements in the gastrocnemius and the effect of Compound A therapy in a murine model of cancer cachexia |
| Q33893441 | Mining the TRAF6/p62 interactome for a selective ubiquitination motif |
| Q33584306 | Muscle RING finger-1 promotes a maladaptive phenotype in chronic hypoxia-induced right ventricular remodeling |
| Q34603561 | Muscle ring finger 1 mediates cardiac atrophy in vivo |
| Q34760711 | NF-κB inhibition protects against tumor-induced cardiac atrophy in vivo. |
| Q36952213 | Protein quality control and degradation in cardiomyocytes |
| Q37628822 | Seek and destroy: the ubiquitin----proteasome system in cardiac disease. |
| Q33679929 | Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease |
| Q27026951 | Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies |
| Q53548334 | The E3 ubiquitin ligase Asb2β is downregulated in a mouse model of hypertrophic cardiomyopathy and targets desmin for proteasomal degradation. |
| Q34760678 | The ubiquitin ligase MuRF1 protects against cardiac ischemia/reperfusion injury by its proteasome-dependent degradation of phospho-c-Jun. |
Search more.